Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310798445> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4310798445 abstract "Abstract Background: In our patient, who was diagnosed with metastatic colorectal cancer, who received a chemotherapy regimen containing oxaliplatin; We present successful desensitization after omaizumab in addition to our premedication scheme Case presentation: 39 years,F. She underwent hemicolectomy and liver metastasectomy with the diagnosis of metastatic colon adenocarcinoma. Chemotherapy regimen consisting of 5 florauracil + Bevacizumab + Oxaliplatin was started. After completing infusions of 5 florauracil while she was receiving her fourth chemotherapy; In the 20th minute of the oxaliplatin infusion, redness and itching began in the palms. While her whole body was red,she had abdominal pain, low back pain, she had no other systemic findings. His blood pressure was 90/60 mmHg. With premedication, oxaliplatin was given in 12 dilutions of 3 bottles with the M.Castel scheme. In the 11th step, at the 5th minute, redness and itching developed on the face and palms. She stated that she had chest and abdominal pain with hypotansıon. After the current condition was treated, 92 mg of oxaliplatin could be given while the target dose was 120 mg . , a single dose of omalizumab 150 mg sc was administered the day before. Standard premedication was also given. The infusion was prepared as 4 bottles of 16 steps. The first three bottles were completed without any problems. Based on her previous reaction, additional premedication was given after Step 14.The desensitization scheme was successfully completed by taking the target dose of 120 mg in total. Conclusıons: We were able to reach the target oxaliplatin dose successfully after our omalizumab administration an additional day before. Although more studies are needed on this subject, we think that omalizumab can be added to the standard premedication schemes of clinics in high-risk patients." @default.
- W4310798445 created "2022-12-18" @default.
- W4310798445 creator A5011145910 @default.
- W4310798445 creator A5054811810 @default.
- W4310798445 date "2022-12-06" @default.
- W4310798445 modified "2023-10-17" @default.
- W4310798445 title "Successful Oxaliplatin Desensitization After Omalizumab Administration" @default.
- W4310798445 cites W1835851824 @default.
- W4310798445 cites W2097643886 @default.
- W4310798445 cites W2117634047 @default.
- W4310798445 cites W2121368761 @default.
- W4310798445 cites W2136807646 @default.
- W4310798445 cites W2137448778 @default.
- W4310798445 doi "https://doi.org/10.21203/rs.3.rs-2313500/v1" @default.
- W4310798445 hasPublicationYear "2022" @default.
- W4310798445 type Work @default.
- W4310798445 citedByCount "0" @default.
- W4310798445 crossrefType "posted-content" @default.
- W4310798445 hasAuthorship W4310798445A5011145910 @default.
- W4310798445 hasAuthorship W4310798445A5054811810 @default.
- W4310798445 hasBestOaLocation W43107984451 @default.
- W4310798445 hasConcept C121608353 @default.
- W4310798445 hasConcept C126322002 @default.
- W4310798445 hasConcept C141071460 @default.
- W4310798445 hasConcept C170493617 @default.
- W4310798445 hasConcept C2776694085 @default.
- W4310798445 hasConcept C2778300832 @default.
- W4310798445 hasConcept C2779779143 @default.
- W4310798445 hasConcept C2780955771 @default.
- W4310798445 hasConcept C2780962732 @default.
- W4310798445 hasConcept C2781413609 @default.
- W4310798445 hasConcept C42219234 @default.
- W4310798445 hasConcept C526805850 @default.
- W4310798445 hasConcept C71924100 @default.
- W4310798445 hasConceptScore W4310798445C121608353 @default.
- W4310798445 hasConceptScore W4310798445C126322002 @default.
- W4310798445 hasConceptScore W4310798445C141071460 @default.
- W4310798445 hasConceptScore W4310798445C170493617 @default.
- W4310798445 hasConceptScore W4310798445C2776694085 @default.
- W4310798445 hasConceptScore W4310798445C2778300832 @default.
- W4310798445 hasConceptScore W4310798445C2779779143 @default.
- W4310798445 hasConceptScore W4310798445C2780955771 @default.
- W4310798445 hasConceptScore W4310798445C2780962732 @default.
- W4310798445 hasConceptScore W4310798445C2781413609 @default.
- W4310798445 hasConceptScore W4310798445C42219234 @default.
- W4310798445 hasConceptScore W4310798445C526805850 @default.
- W4310798445 hasConceptScore W4310798445C71924100 @default.
- W4310798445 hasLocation W43107984451 @default.
- W4310798445 hasOpenAccess W4310798445 @default.
- W4310798445 hasPrimaryLocation W43107984451 @default.
- W4310798445 hasRelatedWork W1968426456 @default.
- W4310798445 hasRelatedWork W1996270707 @default.
- W4310798445 hasRelatedWork W2018158928 @default.
- W4310798445 hasRelatedWork W2066199524 @default.
- W4310798445 hasRelatedWork W2375206374 @default.
- W4310798445 hasRelatedWork W2375984193 @default.
- W4310798445 hasRelatedWork W2379856106 @default.
- W4310798445 hasRelatedWork W2394588226 @default.
- W4310798445 hasRelatedWork W2465617904 @default.
- W4310798445 hasRelatedWork W4286270430 @default.
- W4310798445 isParatext "false" @default.
- W4310798445 isRetracted "false" @default.
- W4310798445 workType "article" @default.